Welcome to our dedicated page for Crescent Biopharma news (Ticker: cbio), a resource for investors and traders seeking the latest updates and insights on Crescent Biopharma stock.
Catalyst Biosciences, Inc. (CBIO) is a clinical-stage biopharmaceutical innovator advancing protease-based therapies for hemophilia and related disorders. This news hub provides investors and healthcare stakeholders with timely updates on the company's scientific progress and operational developments.
Access curated announcements including clinical trial milestones, regulatory filings, and strategic partnership details. Our aggregation ensures you stay informed about Catalyst's pipeline advancements and financial initiatives without needing to monitor multiple sources.
Key updates cover therapeutic candidate progress, peer-reviewed research publications, and resource allocation strategies. All content is vetted for relevance to Catalyst's core mission of developing novel treatments for serious hematologic conditions.
Bookmark this page for streamlined access to Catalyst Biosciences' latest developments. Check back regularly for objective reporting on innovations in protease engineering and patient-focused therapeutic solutions.
Catalyst Biosciences (NASDAQ: CBIO) announced that Clinton Musil has been granted a non-qualified stock option to purchase 140,000 shares of common stock. This is part of his inducement package as the new Chief Financial Officer, effective July 1, 2020. The option has a ten-year term with an exercise price of $5.88 and will vest over four years. Catalyst focuses on developing treatments for rare hematologic conditions and has multiple clinical programs, including MarzAA, a next-generation treatment for hemophilia, set for a Phase 3 study in late 2020.
Catalyst Biosciences (NASDAQ:CBIO) has been added to the Russell 2000 Index effective June 29, 2020. This inclusion, resulting from the Russell index reconstitution, ranks the company among the 4,000 largest U.S. stocks based on market capitalization. Membership in the Russell 2000 also means inclusion in growth and value style indices. Russell indices are widely used by investment managers, with approximately $9 trillion in assets benchmarked against them. Catalyst is focused on innovative treatments for rare hematologic disorders, utilizing its proprietary protease engineering platform.
Catalyst Biosciences (NASDAQ: CBIO) announced two presentations at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, scheduled for July 12-14, 2020. The presentations will focus on marzeptacog alfa (activated), a next-generation treatment for hemophilia. Key topics include a Phase 1 study detailing pharmacokinetics and safety, and population pharmacokinetics simulations for dose selection in Phase 3 trials. Catalyst aims to address unmet needs in rare hematologic disorders with its protease engineering platform, and its lead candidate is set for a Phase 3 study later this year.
Catalyst Biosciences (NASDAQ: CBIO) has successfully closed an underwritten public offering of 4,615,384 shares at $6.50 each, generating $30 million in gross proceeds. The funds will support general corporate purposes including R&D for its complement program and clinical activities for marzeptacog alfa and dalcinonacog alfa. The offering was managed by Raymond James & Associates, Inc., with other partners in the underwriting process. Catalyst has previously filed a shelf registration statement for this offering, aiming to enhance its financial positioning amidst ongoing clinical developments.
Catalyst Biosciences (NASDAQ: CBIO) has appointed Charles Democko as Senior Vice President of Regulatory Affairs, bringing over 20 years of experience in the field. He will spearhead the regulatory strategy for the company’s portfolio targeting rare hematologic and systemic complement-mediated disorders. Democko's previous leadership role at CytomX and his track record in successful marketing applications are expected to bolster Catalyst’s regulatory efforts as it prepares for key milestones. The company’s advanced product candidates include SQ MarzAA and subcutaneous dalcinonacog alfa (DalcA), with Phase 3 trials planned for late 2020.
Catalyst Biosciences (NASDAQ: CBIO) presented preclinical data on its hemophilia B gene therapy, CB 2679d-GT, at the World Federation of Hemophilia Virtual Summit. The therapy demonstrated a 4-fold reduction in blood loss and an 8-fold decrease in bleeding time compared to the Padua variant in mice. Additionally, a pilot study showed stable FIX expression levels above baseline in non-human primates. Catalyst's innovative gene therapy could offer advantages over existing AAV-based options. Future studies, including a Phase 3 trial for SQ MarzAA, are planned for late 2020.
Catalyst Biosciences (NASDAQ: CBIO) announced a public offering of its common stock, subject to market conditions. The company plans to grant underwriters a 30-day option to purchase an additional 15% of shares. Proceeds will support general corporate purposes, including research, development activities for marzeptacog alfa and dalcinonacog alfa, and working capital needs. The offering is based on a previously effective shelf registration statement with the SEC. Raymond James & Associates acts as the sole book-running manager.
Catalyst Biosciences (NASDAQ: CBIO) plans to present a corporate overview at the Raymond James Human Health Innovation Conference on June 18, 2020. CEO Nassim Usman, Ph.D. will lead the presentation at 3:00 PM ET. A live webcast and a recorded version will be accessible for 90 days thereafter. Catalyst is focused on developing treatments for rare hematologic disorders with advanced programs in hemophilia and partnerships including a gene therapy project for age-related macular degeneration with Biogen. More details can be found on their website.
Catalyst Biosciences (NASDAQ: CBIO) announced the completion of its Phase 1 MAA-102 study for Marzeptacog alfa (MarzAA), demonstrating its potential as a subcutaneous treatment for episodic bleeding in hemophilia patients. The company plans to start a Phase 3 trial evaluating MarzAA in 2020. The Phase 1 study results highlighted safety and pharmacokinetic profiles, with positive interim data presented earlier this year. The successful advancement positions Catalyst to address unmet needs in the hemophilia market, expected to disrupt multi-billion dollar treatment paradigms.
FAQ
What is the current stock price of Crescent Biopharma (cbio)?
What is the market cap of Crescent Biopharma (cbio)?
